Skip to main content
. 2018 Feb 9;10(4):e7918. doi: 10.15252/emmm.201707918

Figure 1. Nilotinib has anti‐metastatic activity in CRC.

Figure 1

  1. Nilotinib anti‐invasive activity in a panel of CRC cell lines. Percentage of cell inhibition in Boyden chambers containing 1 mg/ml Matrigel for the indicated CRC cell lines incubated with 100 nM nilotinib (mean ± SEM; n = 3).
  2. Nilotinib activity in Boyden chambers and spheroid assays. HCT116 cells incubated with 100 nM nilotinib or DMSO (control) were seeded in the upper compartment of a Boyden chamber containing 1 mg/ml Matrigel for 24 h or embedded as spheroids in collagen I matrix for 72 h and then imaged by phase‐contrast microscopy. The histogram shows the percentage of migrating cells in the collagen I matrix normalized to control condition set at 100% (mean ± SEM; n = 3 independent experiments with six replicates; *P < 0.05 Student's t‐test). The quantification of nilotinib anti‐invasive activity in HCT116 cells is shown in panel (C).
  3. Dose–response curve of nilotinib effect on CRC cell invasion. Percentage of cell invasion (relative to control) in Boyden chambers containing 1 mg/ml Matrigel of HT29 (▲) and HCT116 (■) CRC cells treated with the indicated concentrations of nilotinib (mean ± SEM; n = 3).
  4. Nilotinib anti‐metastatic activity in nude mice. HCT116 cells were injected in the spleen of nude mice (n = 11/group). After 4 weeks of nilotinib treatment, livers were removed. Representative images of livers (black arrowheads indicate metastasis) and metastatic index of animals treated daily with vehicle or 50 mg/kg nilotinib (oral administration) (mean ± SEM; n = 11/group; *P < 0.05 Student's t‐test).

Source data are available online for this figure.